Based on the response surface methodology-central composite design (RSM-CCD), an optimum formulation of SA-SMEDDS, consisting of ethyl oleate (oil, 12.30%), Cremophor-EL (surfactant, 66.25%), 1,2-propanediol (cosurfactant, 21.44%), and drug loading (50 mg/g), was obtained
Participants also lost on average about 11.5% to 15.3% of body weight on retatrutide, versus 2.6% with the placebo
For most researchers, starting with the core PTD-DBM/valproic acid/microneedling protocol before adding additional compounds allows clearer assessment of what is working
(2018) 97:e11946
Methods: PubMed, EMBASE and Cochrane Library databases were searched to identify eligible randomized controlled trials